Beam Therapeutics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BEAM Nasdaq 2830 beamtx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Beam Therapeutics Inc.

Will IP Theft Allegations Against YolTech and Serapha Bio Change Beam Therapeutics' (BEAM) Narrative - Sep 30th, 2026 7:23 pm
Beam sues 2 biotechs, alleging theft of base editing trade secrets - Sep 29th, 2026 12:34 pm
Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity - Sep 29th, 2026 7:00 am
As Claude Enters the Gene-Editing Arena, There’s Still a Long-Term Case for BEAM Stock - Sep 28th, 2026 3:02 pm
Cathie Wood Makes $64 Million Bet on Two Stocks - Sep 28th, 2026 1:11 pm
Anthropic AI Discovery Gene-Editing Stocks Falling - Sep 24th, 2026 6:46 am
Beam Therapeutics (BEAM) Stock Could Trade At A Premium As Gene Editing Interest Grows - Sep 23rd, 2026 7:14 pm
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon - Sep 23rd, 2026 6:22 am
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - Sep 22nd, 2026 7:26 am
Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names - Sep 22nd, 2026 5:10 am
In Vivo Gene Editing Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036) - Sep 18th, 2026 9:38 am
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry? - Sep 18th, 2026 7:44 am
Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout - Sep 17th, 2026 2:09 pm
Beam Therapeutics (BEAM) Restored AAT Levels. Can BEAM-302 Deliver Clinical Benefit? - Sep 10th, 2026 5:33 pm
3 Promising Genomics Stocks in the Spotlight in 2026 - Sep 8th, 2026 10:46 am
Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment - Sep 8th, 2026 7:22 am
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 - Sep 8th, 2026 4:00 am
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer - Sep 1st, 2026 5:00 am
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences - Aug 31st, 2026 5:00 am